ARTICLE | Clinical News
PDC31: Phase I data
January 21, 2013 8:00 AM UTC
A Phase I trial in healthy women with primary dysmenorrhea showed that PDC31 dose-dependently relieved pain and reduced intrauterine pressure. PDC31 was well tolerated with no dose-limiting toxicities...